

Laura E McCoy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2156920/publications.pdf>

Version: 2024-02-01

39
papers

6,820
citations

218381

26
h-index

315357

38
g-index

51
all docs

51
docs citations

51
times ranked

12687
citing authors

#	ARTICLE	IF	CITATIONS
1	Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. <i>Nature</i> , 2022, 601, 110-117.	13.7	280
2	SARS-CoV-2-specific memory B cells can persist in the elderly who have lost detectable neutralizing antibodies. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	24
3	SARS-CoV-2 antibody responses in patients with acute leukaemia. <i>Leukemia</i> , 2021, 35, 289-292.	3.3	26
4	Vaccine responses in ageing and chronic viral infection. <i>Oxford Open Immunology</i> , 2021, 2, .	1.2	3
5	SARS-CoV-2 evolution during treatment of chronic infection. <i>Nature</i> , 2021, 592, 277-282.	13.7	802
6	Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. <i>Nature</i> , 2021, 593, 136-141.	13.7	648
7	The effect of spike mutations on SARS-CoV-2 neutralization. <i>Cell Reports</i> , 2021, 34, 108890.	2.9	200
8	SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity. <i>Science Advances</i> , 2021, 7, .	4.7	107
9	Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. <i>Nature</i> , 2021, 596, 417-422.	13.7	549
10	Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant. <i>Immunity</i> , 2021, 54, 1276-1289.e6.	6.6	112
11	Failure to seroconvert after two doses of BNT162b2 SARS-CoV-2 vaccine in a patient with uncontrolled HIV. <i>Lancet HIV</i> , 2021, 8, e317-e318.	2.1	36
12	Neutralizing Antibody Responses After SARS-CoV-2 Infection in End-Stage Kidney Disease and Protection Against Reinfection. <i>Kidney International Reports</i> , 2021, 6, 1799-1809.	0.4	13
13	Defining Potential Therapeutic Targets in Coronavirus Disease 2019: A Cross-Sectional Analysis of a Single-Center Cohort. , 2021, 3, e0488.		2
14	Sex differences in immunological responses to COVID-19: a cross-sectional analysis of a single-centre cohort. <i>British Journal of Anaesthesia</i> , 2021, 127, e75-e78.	1.5	4
15	Antibodies from Rabbits Immunized with HIV-1 Clade B SOSIP Trimers Can Neutralize Multiple Clade B Viruses by Destabilizing the Envelope Glycoprotein. <i>Journal of Virology</i> , 2021, 95, e0009421.	1.5	5
16	Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primates. <i>PLoS Pathogens</i> , 2021, 17, e1009736.	2.1	18
17	Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID-19 with B-cell malignancies. <i>British Journal of Haematology</i> , 2021, 195, 706-709.	1.2	16
18	Influence of IL-6 levels on patient survival in COVID-19. <i>Journal of Critical Care</i> , 2021, 66, 123-125.	1.0	7

#	ARTICLE	IF	CITATIONS
19	To bnAb or Not to bnAb: Defining Broadly Neutralising Antibodies Against HIV-1. <i>Frontiers in Immunology</i> , 2021, 12, 708227.	2.2	26
20	Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV. <i>Nature Communications</i> , 2021, 12, 5839.	5.8	67
21	Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings. <i>PLoS Pathogens</i> , 2020, 16, e1008817.	2.1	105
22	Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. <i>Science</i> , 2020, 370, 1339-1343.	6.0	735
23	HIV envelope trimer-elicited autologous neutralizing antibodies bind a region overlapping the N332 glycan supersite. <i>Science Advances</i> , 2020, 6, eaba0512.	4.7	18
24	Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers. <i>Lancet, The</i> , 2020, 396, e6-e7.	6.3	196
25	Super Potent Bispecific Llama VHH Antibodies Neutralize HIV via a Combination of gp41 and gp120 Epitopes. <i>Antibodies</i> , 2019, 8, 38.	1.2	25
26	HIV-1 remission following CCR5 Δ 32 haematopoietic stem-cell transplantation. <i>Nature</i> , 2019, 568, 244-248.	13.7	447
27	The expanding array of HIV broadly neutralizing antibodies. <i>Retrovirology</i> , 2018, 15, 70.	0.9	38
28	Electron-Microscopy-Based Epitope Mapping Defines Specificities of Polyclonal Antibodies Elicited during HIV-1 BG505 Envelope Trimer Immunization. <i>Immunity</i> , 2018, 49, 288-300.e8.	6.6	175
29	Circulating and intrahepatic antiviral B cells are defective in hepatitis B. <i>Journal of Clinical Investigation</i> , 2018, 128, 4588-4603.	3.9	208
30	Identification and specificity of broadly neutralizing antibodies against HIV. <i>Immunological Reviews</i> , 2017, 275, 11-20.	2.8	198
31	Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches. <i>Immunity</i> , 2017, 46, 1073-1088.e6.	6.6	286
32	Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model. <i>Cell Reports</i> , 2017, 21, 222-235.	2.9	58
33	HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies. <i>Immunity</i> , 2016, 45, 483-496.	6.6	335
34	Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies. <i>Cell Reports</i> , 2016, 16, 2327-2338.	2.9	216
35	Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies. <i>PLoS Pathogens</i> , 2015, 11, e1005110.	2.1	78
36	Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine Design. <i>Immunity</i> , 2015, 43, 959-973.	6.6	177

#	ARTICLE	IF	CITATIONS
37	Molecular Evolution of Broadly Neutralizing Llama Antibodies to the CD4-Binding Site of HIV-1. PLoS Pathogens, 2014, 10, e1004552.	2.1	34
38	A gp41 MPER-specific Llama VHH Requires a Hydrophobic CDR3 for Neutralization but not for Antigen Recognition. PLoS Pathogens, 2013, 9, e1003202.	2.1	64
39	Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization. Journal of Experimental Medicine, 2012, 209, 1091-1103.	4.2	91